Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:10 p.m.

    📋 Travere Therapeutics, Inc (TVTX) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 16:32:02

    Event Type: Clinical Trial Update

    Event Details:

    Travere Therapeutics, Inc (TVTX) Announces Clinical Trial Update Travere Therapeutics, Inc (TVTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Registrant’s Telephone Number

    🔬 Clinical Development Pipeline (Travere Therapeutics, Inc):

    Product Type Development Stage Therapeutic Area Source
    Irbesartan DRUG Phase PHASE3 Focal Segmental Glomerulosclerosis ClinicalTrials.gov
    Sparsentan DRUG Phase PHASE2 Focal Segmental Glomerulosclerosis ClinicalTrials.gov
    No sparsentan DRUG Phase PHASE1 Proteinuric Renal Disease ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Pantothenate Kinase-Associated Neurodegeneration ClinicalTrials.gov
    Fosmetpantotenate DRUG Phase PHASE3 Pantothenate Kinase-Associated Neurodegeneration ClinicalTrials.gov
    RE-021, sparsentan DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    Pegtibatinase DRUG Phase PHASE3 Homocystinuria ClinicalTrials.gov
    RE-021 (Sparsentan) DRUG Phase PHASE2 Focal Segmental Glomerulosclerosis ClinicalTrials.gov
    Dapagliflozin DRUG Phase PHASE3 Immunoglobulin A Nephropathy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Travere Therapeutics, Inc
    • Ticker Symbol: TVTX

Search

News categories